Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ATTO-3712 · 1 trial · 4 indications
The primary analysis will describe the incidence of AEs and laboratory abnormalities. AEs will be coded according to system organ class and preferred term using the Medical Dictionary for Regulatory Activities (MedDRA, version 28.0 or the current version). Their severity will be graded using the NCI CTCAE v5.0 or the current version.
Clinical laboratory parameters (hematologic and blood chemistry) will be summarized by visit
ECG findings (including QT abnormalities) will be summarized by visit.
Vital signs (systolic and diastolic blood pressure, temperature, heart rate) will be summarized by visit.
| Arm | Type | Description |
|---|---|---|
| ATTO-3712 single dose IV | EXPERIMENTAL | ATTO-3712 Dose level cohorts receiving a single dose IV |
| Placebo single dose IV | PLACEBO_COMPARATOR | Placebo preparation to match Experimental Arm with single dose IV |
| ATTO-3712 single dose SC | EXPERIMENTAL | ATTO-3712 dose level cohorts receiving a single dose SC |
| Placebo single dose SC | PLACEBO_COMPARATOR | Placebo preparation to match Experimental Arm with single dose SC |
| ATTO-3712 multiple dose SC | EXPERIMENTAL | ATTO-3712 administered to dose level cohorts in multiple SC doses |
| Placebo multiple dose SC | PLACEBO_COMPARATOR | Placebo preparation to match Experimental Arm administered in multiple SC doses |
| Name | Type | Description |
|---|---|---|
| ATTO-3712 | DRUG | ATTO-3712 |
| Placebo | DRUG | Placebo preparation to match ATTO-3712 dose |
Parts 1\&2 (Healthy Volunteers) Key Inclusion Criteria: * Any sex or gender who is 18 to 65 years old, inclusive, at Screening. * Body weight of 50 to 125 kg and body mass index (BMI) between 18.5 and 35 kg/m2 * Considered in good general health based on medical history, physical exam, 12-lead ECG,...
ATTO-3712 is an investigational small molecule being developed by Alamar Biosciences for use in dermatology. It is currently being studied in a Phase 1 clinical trial in healthy volunteers and patients with atopic dermatitis, also known as atopic eczema. The drug is not yet approved and remains in clinical development.
ATTO-3712 is being developed by Alamar Biosciences, Inc., a biopharmaceutical company traded on the stock exchange under the ticker symbol ALMR. The company is conducting a Phase 1 clinical trial to evaluate the safety, tolerability, and pharmacokinetics of the drug in healthy volunteers and patients with atopic dermatitis.
ATTO-3712 is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The ongoing Phase 1 trial is designed to assess the safety, tolerability, and pharmacokinetics of ATTO-3712 in healthy volunteers and patients with atopic dermatitis.
ATTO-3712 is being studied in one active Phase 1 clinical trial with the identifier NCT07205081. The trial is titled 'Safety, Tolerability and PK of ATTO-3712 in Healthy Volunteers and Patients With Atopic Dermatitis' and is enrolling 72 participants in the United States and Canada. The study is randomized, double-blind, and placebo-controlled.
Yes, ATTO-3712 is being studied in atopic dermatitis, also referred to as atopic eczema. The Phase 1 clinical trial NCT07205081 includes patients with atopic dermatitis as well as healthy volunteers. The study is currently active but not recruiting participants, and it is being conducted at sites in the United States and Canada.